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Abstract
We assessed changes in functional connectivity by fMRI (functional magnetic resonance imaging) and cognitive measures in
otherwise neurologically asymptomatic people with HIV (PWH) switching combination antiretroviral therapy (cART). In a
prospective study (baseline and follow-up after at least 4 months), virologically suppressed PWH switched non-nuclease re-
verse-transcriptase inhibitors (NNRTI; tenofovir-DF/emtricitabine with efavirenz to rilpivirine) and integrase-strand-transfer
inhibitors (INSTI; tenofovir-DF/emtricitabine with raltegravir to dolutegravir). PWH were assessed by resting-state fMRI and
stop-signal reaction time (SSRT) task fMRI as well as with a cognitive battery (CogState™) at baseline and follow-up. Switching
from efavirenz to rilpivirine (n = 10) was associated with increased functional connectivity in the dorsal attention network (DAN)
and a reduction in SSRTs (p = 0.025) that positively correlatedwith the time previously on efavirenz (mean = 4.8 years, p = 0.02).
Switching from raltegravir to dolutegravir (n = 12) was associated with increased connectivity in the left DAN and bilateral
sensory-motor and associative visual networks. In the NNRTI study, significant improvements in the cognitive domains of
executive function, working memory and speed of visual processing were observed, whereas no significant changes in cognitive
function were observed in the INSTI study. Changes in fMRI are evident in PWHwithout perceived neuropsychiatric complaints
switching cART. fMRI may be a useful tool in assisting to elucidate the underlying pathogenic mechanisms of cART-related
neuropsychiatric effects.
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Introduction
Earlier treatment initiation and wider access to combination
antiretroviral therapy (cART) have resulted in a significant
decline in the incidence of HIV-associated central nervous
system (CNS) diseases (Garvey et al. 2011). Despite this,
neuropsychiatric events, such as cognitive deficits, anxiety,
depression and insomnia, are frequently reported in people
with HIV (PWH) on effective cART (Knights et al. 2017).
Alongside traditional pathogenic mechanisms such as the leg-
acy effect of HIV in CNS prior to cART initiation and CNS
immune activation, antiretroviral toxicity may be a potential
pathogenic factor responsible for the occurrence of these neu-
ropsychiatric symptoms (Underwood et al. 2014). Indeed,
efavirenz, a highly efficacious non-nucleoside reverse-tran-
scriptase inhibitor (NNRTI), has been associated with neuro-
psychiatric symptoms in 20–40% of patients which may per-
sist for several years after treatment initiation (Zhuang et al.
2017; Sacktor et al. 2006; McCutchan et al. 2007). Integrase-
strand-transfer inhibitors (INSTI) have also been linked to an
Alan Winston and Jaime H. Vera contributed equally to this work.
* Sofia Toniolo
sofia.toniolo@ndcn.ox.ac.uk
1 Clinical Imaging Sciences Centre, Brighton and Sussex Medical
School, Knightsgate Road, Falmer Campus, Brighton BN1 9RR, UK
2 Present address: Nuffield Department of Clinical Neurosciences,
University of Oxford, New Radcliffe House, Walton St.,
Oxford OX2 6BW, UK
3 Department of Infectious Disease, Faculty of Medicine, St Mary’s
Campus, Imperial College London, Praed Street, London W2 1NY,
UK
4 Division of Infection and Immunity, School of Medicine, Cardiff
University, UHW Main Building, Heath Park, Cardiff CF14 4XN,
UK
5 Department of HIV Medicine, Chelsea and Westminster NHS
Foundation Trust, 369 Fulham Road, London SW10 9NH, UK
6 Department of Global Health and Infection, Brighton and Sussex
Medical School, Brighton BN1 9PX, UK
Journal of NeuroVirology
https://doi.org/10.1007/s13365-020-00853-0
increased risk of neuropsychiatric adverse events, with
dolutegravir being associated with the highest rate of discon-
tinuation compared with other INSTI (2–6%) (Elzi et al. 2017;
Hoffmann et al. 2017).What impact antiretroviral drugs might
have on brain activity and how it correlates with covert neu-
ropsychiatric symptoms remains poorly described.
Functional MRI (fMRI) is an imaging modality that may
provide valuable information on the effects of different cART
regimens on the CNS bymeasuring changes in brain function-
al connectivity at rest or in response to tasks (Wise and Tracey
2006). The aim of this study is to assess changes in functional
connectivity by fMRI and cognitive and behavioural measures
in neurologically asymptomatic PWH participating in studies
assessing changes in NNRTI and INSTI.
Methods
Subject selection and study design
PWHwere enrolled in two separate phase IV, open-label stud-
ies conducted in 3 UK sites (Chelsea and Westminster
Hospital, St. Mary’s Hospital London and the Royal Sussex
County Hospital) between January 2016 and January 2018.
Inclusion criteria for both studies included no history of
subjective or objective neurological or psychiatric symptoms,
age ≥ 18 years, plasma HIV RNA < 40 copies/mL for at least
3 months, CD4 cell count > 50 cells/μL and being stable on
the same cART regimen for at least 12 weeks (tenofovir-DF/
emtricitabine/efavirenz for the first study (NNRTI study) and
tenofovir-DF/emtricitabine and raltegravir for the second
study (INSTI study) (see Fig. 1).
Subjects were excluded if they had previous exposure to
rilpivirine in the NNRTI study and dolutegravir in the INSTI
study, viral hepatitis co-infection, evidence of HIV drug resis-
tance mutations, use of disallowed concomitant medication or
current self-reported recreational drug use or alcohol abuse.
In the NNRTI study, all eligible participants (n = 10) were
switched from the fixed-dose combination tenofovir-DF/
emtricitabine/efavirenz to tenofovir-DF/emtricitabine/
rilpivirine for 6 months. In the INSTI study, participants were
randomized in a 1:2 fashion to either remain on the same
cART drug regimen or switch to tenofovir-DF/emtricitabine
and dolutegravir 50mg once daily for the duration of the study
period (4 months). Randomization accounted for a total of 12
patients switching to dolutegravir and of 8 patients that
remained on raltegravir. At each study visit, all study partici-
pants were specifically questioned and assessed by a research
nurse or doctor about any psychiatric or neurological adverse
events.
Standard protocol approvals, registrations and
patient consents
The studies were conducted in accordance with the
Declaration of Helsinki, the Uniform Requirements for
Manuscripts submitted to Biomedical Journals, were ap-
proved by the research ethics committee, the UK regulatory
authority and Medicines and Healthcare products Regulatory
Agency (MRHA) and were registered with the EudraCT trials
database (2014-002284-15) and (2014-003710-84). All sub-
jects gavewritten informed consent prior to study initiation for
both studies. The contracts between academic institutions and
the funders stated clearly independence in terms of design,
Fig. 1 Study design for the
NNRTI and INSTI studies
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analysis and dissemination of the results. The present manu-
script was analysed by investigators that have never received
any funding from HIV-related pharmaceutical companies as
described in the disclosures. Furthermore, the neuroimaging
analysis was conducted blinded to the drug names to prevent
the imaging specialist from bias.
Study procedures
Clinical assessments
Cognitive testing Cognitive testing was performed at baseline
and at the final study visit using CogState™ (CogState™ Ltd.,
Melbourne, Australia), a computerized battery previously val-
idated in PWH (Cysique et al. 2006) to assess processing
speed, attention, visual learning, spatial problem solving,
working memory and executive functions.
Cognitive results were compared with standardized norma-
tive data provided by CogState™ and transformed into Z-
scores. Within the study time point, changes were tested using
the Wilcoxon signed-rank test.
Patient-reported outcome measures Participants completed
the following questionnaires at baseline and follow-up:
Patient Health Questionnaire-9 (PHQ-9) (Kroenke et al.
2001), Beck’s Depression Inventory (BDI) (Beck et al.
1961), Pittsburgh Sleep Quality Index (PSQI) (Buysse et al.
1989) and Hospital and Anxiety and Depression Scale
(HADS) (Zigmond and Snaith 1983). Within the study time
point, changes were tested using the Wilcoxon signed-rank
test.
Imaging assessments
Resting-state network fMRI analysis Data pre-processing: All
imaging was obtained using a 3.0T MR scanner (SIEMENS
MAGNETOMVerio syngo MR B17) with a 32-channel head
coil for both visits. The following scans were collected from
each studied subject at baseline and follow-up: a high-
resolution 3D fluid-attenuated inversion recovery (FLAIR)
sequence (TE = 394 ms, TR = 5000 ms, TI = 1800 ms, field-
of-view = 250 mm, 160 contiguous slices of 1 mm thickness,
voxel size = 1 mm3); a three-dimension (3D) magnetization-
prepared rapid gradient-echo (MPRAGE) (TE = 2.98 ms,
TR = 2300 ms, TI = 900 ms, flip angle = 9°, field-of-view =
256 mm, 160 contiguous slices of 1 mm thickness, voxel
size = 1 mm3); and a BOLD response-sensitive echo-planar
imaging (EPI) sequence (TE = 30 ms, TR = 2000 ms, flip an-
gle = 80°, field-of-view = 192 mm, 35 interleaved slices of
3 mm thickness with no gap, voxel size = 3 mm3, duration
10.06 min) for resting-state fMRI. Participants were instructed
to remain still with their eyes closed and not think of anything
specific while trying to stay awake. Nine out of 10 in the
NNRTI study, 9 out of 11 people on the dolutegravir arm
and 7 out of 8 on the raltegravir arm in the INSTI study gave
consent to perform the fMRI task so an additional sequence
with the same parameters as the resting state was acquired
while participants performed the stop-signal task (SST) be-
havioural task. According to the inclusion criteria, FLAIR
scans were reviewed to exclude the presence of significant
macroscopic brain abnormalities. For all MRI scans, resting-
state fMRI data analysis was carried out using FMRIB
Software Library (FSL) (Jenkinson et al. 2012). We first
discarded the first 4 volumes to allow steady-state magnetiza-
tion. Each dataset underwent motion correction with
MCFLIRT (Jenkinson et al. 2002a), non-brain tissue removal
with brain extraction tool (BET) (Jenkinson et al. 2002b),
nonlinear registration of the functional images to the main
structural image with FNIRT (FMRIB’s nonlinear image reg-
istration tool) and denoising using independent component
analysis-based Automatic Removal Of Motion Artifacts
(ICA-AROMA) (Pruim et al. 2015). The images extracted
from AROMA were then normalized to the Montreal
Neurological Institute (MNI) standard space (2 mm isotropic).
Grand-mean intensity normalization and spatial smoothing
with a Gaussian kernel of 5.0 mm full width at half-
maximum (FWHM) were subsequently performed.
fMRI RSN first-level analysis: A group-level ICA was per-
formed across all subjects and all scans using MELODIC
(Beckmann and Smith 2004). First, the previously pre-
processed 4D dataset was temporally transformed by concat-
enation into a single time series. This new 4D image was then
separated into different independent components (ICs).
We decided to use 2 different IC dimensionalities (number
of IC components) for maximizing the matching between the
data generated by our sample and previously described RSNs.
In the NNRTI study, we did not a priori set the number of
component, and within the 38 group-level IC maps originated
by MELODIC, we selected 8 cognitively relevant networks,
i.e. default mode network (DMN), executive network (EXE),
dorsal attention network (DAN), ventral attention network
(VAN), anterior limbic network (ANTLIMB), posterior lim-
bic network (POSTLIMB) and left and right frontoparietal
network (LFP and RFP).
For the INSTI study, we set the ICs to 20 according to the
20 RSN model by Smith et al. (Smith et al. 2009), and within
the group-level IC maps originated by MELODIC, we select-
ed 10 networks of interest, i.e. DMN, EXE, salience network
(SAL), DAN, VAN, limbic network (LIMB), LFP and RFP,
sensory-motor network (SM) and associative visual network
(VISAS). The identification of each network was defined ac-
cording to previously described RSNs (Smith et al. 2009;
Thomas Yeo et al. 2011; Dipasquale and Cercignani 2016;
Laird et al. 2011), with the associative visual network corre-
sponding to the lateral visual areas by Smith et al. (Smith et al.
2009). A visual inspection of each component spatial profile
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to ensure the effectiveness of the matching between the RSNs
originated byMELODIC and previously described RSNs was
performed. This procedure allows us to check which RSN
model describes best the networks generated by our data
sample.
fMRI RSN second-level analysis: Subject-specific IC maps
were obtained using dual regression (Filippini et al. 2009) and,
subsequently, a second-level analysis testing the between-
session group difference was performed using FSL randomize
(Winkler et al. 2014) through a 2-sample t test on the between-
session difference image with the number of iterations set to
2000. A binary mask of every network was obtained by a one-
sample t test and the analysis was restricted within the mask.
We estimated 4 contrasts: within-session means and the with-
in-subject, between-session differences. The second-level in-
ference was thresholded at a family-wise error (FWE)-
corrected probability of p < 0.05 with threshold-free cluster
enhancement (TFCE).
Stop-signal task fMRI analysis Subjects performed a response
inhibition task, the stop-signal task (SST) inside the scanner as
task fMRI at baseline and follow-up (see Fig. 2). The SST
measures the efficiency of response inhibition, with lower
SSRTs (stop-signal response times) indicating less time re-
quired to inhibit a response (Rae et al. 2014).
Briefly, participants performed a speeded response task
(e.g. indicating whether an arrow points to the left or right).
On “GO” trials, an arrow pointing to the left or right was
presented, and the subjects were instructed to respond as
quickly as possible. On “STOP” trials, a stop signal was pre-
sented concurrently with or just after the target, and partici-
pants had to withhold their response. The onset time of the
stop signal relative to the go stimulus or stop-signal delay
(SSD) changed dynamically throughout the experiment and
the efficiency of response inhibition was estimated by observ-
ing the effects of varying the SSD on the SSRT.
SSD changed dynamically throughout the experiment de-
pending on the subject’s performance, increasing by 50 ms if
the subject inhibited successfully on a STOP trial or converse-
ly decreasing the SSD by 50 ms if inhibition was unsuccess-
ful. Four step-up and step-down algorithms (staircases), with
initial SSD values of 100, 150, 200 and 250 ms respectively,
were used to ensure convergence to inhibition of 50% trials by
the end of the experiment. Average SSD was computed, for
each subject, using the values of the four staircases after the
subject had converged on 50% inhibition (Aron and Poldrack
2006), while SSRTwas estimated by subtracting average SSD
from median correct RT in the GO trials. To improve subject
attentive engagement and motivation over time, a “negative
feedback” cue was presented based on whether the last reac-
tion time (RT) was over 0.95% of the previous RTs. SSRT,
RT and accuracy were compared between time points. Firstly,
we used the Shapiro-Wilk test to assess normality distribution
and then either a paired t test or a Mann-Whitney U test ac-
cording to the normality of the data.
We then looked at associations between SSRT, RT and
accuracy and clinical parameters. As most of the participants
in both studies were of the male gender, no associations be-
tween gender and SSRT/RT were investigated. No significant
associations between SSRT/RT parameters and age were ob-
served. We selected 5 covariates of interest (years with HIV,
years on cART, CD4 count, CD4/8 ratio and years on the
drug) and we performed an ANOVA with repeated measures
on SSRTs, RTs and accuracy using these specific clinical data
as covariates.
Data pre-processing and fMRI SST first-level analysis: All
image processing was done in Statistical Parametric Mapping
Version 12 (SPM12). The first 4 images were discarded in
order to allow steady-state magnetization. Images were
realigned to the mean image, slice time corrected, normalized
to the MNI standard template and smoothed with a Gaussian
kernel of 5.0 mm FWHM.
The following contrasts were estimated and taken to the
second level for each session: STOP correct trials > GO trials
and GO trials > STOP correct trials.
fMRI SST second-level analysis: For the NNRTI study, we
performed a paired t test between images at baseline and after
6 months. For the INSTI study, the between-session differ-
ence image was assessed using ImCalc SPM function in order
to obtain the final within-subjects’ image and a two-sample t
test was used to assess the between-group difference in the 2
groups.
Fig. 2 Behavioural task (SST) experimental model. SSD, stop-signal
delay; RT, response time; SSRT, stop-signal response time
J. Neurovirol.
For all results, we examined two different contrasts, respec-
tively assessing whether participants showed increased or de-
creased fMRI activation between sessions (NNRTI study) or
between groups (INSTI study) for both conditions: STOP >
GO trials and GO > STOP trials. The resulting statistic images
were thresholded at p < 0.05 cluster-based FWE with cluster
formed using p < 0.001 at the voxel level.
Data availability statement The full anonymized dataset for this
project will be deposited in the University of Sussex research
repository as part of the University’s Research Data
Management Policy where all data for this study can be accessed
upon request and approval by the research ethics committee.
Results
Ten participants from the NNRTI study and 20 participants
from the INSTI study (8 in the control arm and 12 in the
switch arm) completed study procedures. Baseline character-
istics are presented in Table 1.
One MRI scan in the switch arm of the INSTI study at
follow-up was corrupted by severe artefacts, so the subject
was excluded from the group MRI analysis. Study drugs were
well tolerated with all patients reporting over 95% adherence
to therapy. No safety or laboratory concerns related to any of
the study drugs were observed. At 4 months, plasma HIV
RNA was < 40 copies/mL in all subjects for both studies.
Effect of switching cART on cognitive testing
In the NNRTI study, no statistically significant differences be-
tween the time points were found in global cognitive scores;
however, a significant improvement in cognitive tests assessing
executive functions, working memory and visual-motor control
were observed (Groton Maze Learning Test, One Back Test and
Groton Maze Chase Test) (see Table 2). No changes in individ-
ual cognitive tests were observed in the INSTI study.
Effect of switching cART on PROMs
In the NNRTI study, a 3% improvement in sleep quality (me-
dian change (IQR) from baseline: 3 (− 2 to 10); p = 0.009 for
the PSQI) and a 4.8% improvement in anxiety symptoms
(median change (IQR) from baseline: 4.8 (− 4.8 to 33); p =
0.053 for HADS) at follow-up were observed following the
switch. No differences in changes of other PROMs were ob-
served and no statistically significant differences were ob-
served in the INSTI study.
Effect of switching cART on resting-state networks
fMRI
In the NNRTI study, over the study period, we observed sig-
nificantly enhanced connectivity of the dorsal attention net-
work (DAN), and in particular of the right superior parietal
lobule (see Fig. 3). No other changes in functional connectiv-
ity among the other 7 networks examined were observed.
In the INSTI study, significantly increased connectivity in the
DAN, VISAS (associative visual) and SM (sensory-motor) net-
works was observed over the study period (see Fig. 4). Within
the DAN, the brain areas that showed an increase in functional
connectivity were the left middle frontal gyrus (within the frontal
eye fields), left superior parietal lobule, left supramarginal gyrus
and left superior frontal gyrus. Regarding the VISAS, we found
an enhanced connectivity within the right lateral occipital cortex.
In the SM network, we found a wider increase of functional
connectivity bilaterally in the superior and medial frontal gyrus
and precentral gyrus.
Effect of switching cART on behavioural measures
(SST)
In the NNRTI study, a reduction in SSRT was observed after
switching from efavirenz to rilpivirine (p = 0.025).
Participants showed good response accuracy in both condi-
tions, thus confirming good compliance to the task. The
Table 1 Demographic characteristics for NNRTI and INSTI studies
Parameter NNRTI study (efavirenz to rilpivirine) INSTI study (raltegravir to dolutegravir)
Control arm Switch arm
Number 10 8 12
Age, years median (IQR) 52 (14) 39.5 (15.5) 43 (13)
Male, n (%) 10 (100) 7 (87.5) 12 (100)
White ethnicity, n (%) 10 (100) 5 (62.5) 9 (69.2)
CD4+ count at study entry (cells/μL), median (IQR) 600 (256) 688 (395) 736 (237)
HIV RNA viral load < 40 copies/mL, n (%) 10 (100) 8 (100) 12 (100)
Demographic characteristics for NNRTI and INSTI studies
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reduction in SSRTs between the two conditions was positively
correlated with the duration of efavirenz exposure, F(1,3) =
20.976, p = 0.020, η2 = 0.875. No statistical correlation be-
tween the other values and changes in SSRTs was observed
(see Table 3). In the INSTI study, SSRTs (p = 0.606), mean
RTs (p = 0.724) and accuracy (p = 0.252) were not significant-
ly different between the two groups or between time points.
Effect of switching cART on response inhibition in
fMRI SST
In both studies, the main effects of activation patterns for both
contrasts were in line with previous meta-analysis data on the
SST task. In the NNRTI study, a reduction in BOLD activa-
tion in the STOP > GO contrast was observed after switching
efavirenz to rilpivirine in the right IFG (pars opercularis), right
insula, right prefrontal cortex, right posterior parietal cortex,
right lateral occipital gyrus and left primary, and associative
auditory cortex and left primary motor cortex, but these results
did not survive after correction for multiple comparisons
(FWE). This was also the case for the inverse contrast
rilpivirine to efavirenz, where BOLD activation was observed
in the right paracingulate cortex, right IFG (pars orbitalis and
pars opercularis), bilateral frontal eye fields, right middle fron-
tal gyrus, right pre-SMA, left posterior parietal cortex, right
lateral occipital gyrus and right angular gyrus. The reverse
contrast, GO > STOP, did not show any significant result. In
the INSTI study, the analysis did not show any area of in-
creased or decreased connectivity between time points in
GO > STOP or STOP > GO contrasts.
Discussion
Using a combined fMRI and cognitive behavioural approach, we
were able to identify a dysfunction of the attentional network and
executive functions that were restored by drug switching. From a
neuropsychological perspective, in the NNRTI study, despite
participants being asymptomatic, a significant improvement in
sleep quality (measured by the PSQI) and anxiety symptoms
(HADS) was observed, while in the INSTI study, we found no
changes in any of the PROMs,which is in linewith previous data
(Mora-Peris et al. 2019), suggesting the observed changes are not
just an artefact of repeated measurement. Moreover, these results
Table 2 Changes in cognitive function by study arm (NNRTI study)
Baseline 6 months Changes at 6 months from
baseline
p
value
Cognitive test Cognitive domain Outcome measure Z-scores
(SD)
Z-scores
(SD)
Mean score difference (95% CI)
Identification Attention Speed of performance
log10 milliseconds
− 0.39 (0.48) − 0.34 (0.81) 0.05 (− 0.80/0.91) 0.88
Detection Psychomotor
function
Speed of performance
log10 milliseconds
− 0.65 (0.93) − 0.72 (0.64) − 0.07 (− 0.5/0.42) 0.75
One Card Learning Visual learning Accuracy of
performance
− 0.66 (1.09) − 0.62 (1.6) 0.03 (− 1.11/1.18) 0.94
One Back Working memory Speed of performance
log10 milliseconds
− 0.01 (0.97) − 2.13 (1.02) − 2.11(− 2.7/− 1.4) 0.001
Groton Maze Chase Visual-motor control Moves per second 0.10 (1.02) − 0.61 (0.9) − 0.72 (− 1.20/− 0.20) 0.011
Groton Maze Learning Executive function Total number of errors − 0.06 (0.98) − 2.13 (1.2) − 2.06 (− 2.90/− 1.22) 0.003
SET shifting Executive function Total number of errors − 0.04 (0.96) 0.03 (1.02) 0.07 (− 0.64/0.80) 0.81
Global cognitive
Z-score
Global cognition Z-score − 0.19 (24) − 0.58 (0.78) − 0.24 (− 1.05/0.5) 0.24
SD, standard deviation; CI, confidence interval; p value, two-tailed. Lower scores at Identification, Detection, One Back, Groton Maze Chase, Groton
Maze Learning, SET shifting, Global cognitive score indicate better performance. Higher scores at the One Card Learning task indicate better
performance
Fig. 3 Resting-state connectivity
after switching to rilpivirine
compared with the baseline. Red:
areas of enhanced connectivity
within the DAN (right superior
parietal lobule). Blue: DAN
mask. L, left; R, right
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are in line with previous data reporting that switching from
efavirenz containing to efavirenz-free regimens has a beneficial
impact on sleep quality and anxiety, as well as on executive
function and attention (Vera et al. 2019; Walker and Brown
2018; Knoch et al. 2006). Interestingly, executive function was
also found to be positively affected by drug switching in our
study, measured by an improvement on the Groton Maze
Learning Test and moreover on the SST task, which has become
a standard measure of response inhibition (Logan and Cowan
1984). Data on SST performance in PWH are scarce, though a
recent study reported that drug-naïve PWH showed comparable
SSRTs with respect to healthy controls but longer RTs (Du
Plessis et al. 2015). In the NNRTI study, we found that SSRTs
were longer in participants on efavirenz before switching to
rilpivirine, suggesting a detrimental effect caused by efavirenz
with a loss of correct response inhibition, which might be re-
stored by switching to rilpivirine. Moreover, we observed that
the change in SSRTs between the two conditions was directly
correlated with the duration of efavirenz treatment. The longer
the patients were on efavirenz, the longer the SSRTs were and
the worst the efficacy of response inhibition was. We postulate
that this might reflect a cumulative effect of efavirenz treatment
on the ability to correctly inhibit responses.
Functional connectivity has been extensively used in HIV
clinical research settings (Ernst et al. 2002; Chang et al. 2001;
Schweinsburg et al. 2012). Nevertheless, studies on drug-
induced changes on resting-state networks in HIV populations
are limited. If cART as a whole is taken into consideration, drug-
naïve PWH show a lower functional connectivity in the DMN
compared with healthy controls that could be restored after
12 weeks of cART (Zhuang et al. 2017). Interestingly, other
experimental techniques such as MEG report that even PWH
on effective cART show a disruption of the DMN compared
with healthy controls (Becker et al. 2013), which could be ex-
plained by either the beneficial effect of cART being limited in
restoring the network dysfunction produced by HIV infection or
cART exerting both positive and negative effects on this RSN.
Besides the DMN, increasing observations point towards an
Fig. 4 Resting-state connectivity
after switching to dolutegravir
compared with the baseline. a
DAN: red, areas of enhanced
connectivity within the DAN (left
middle frontal gyrus, left superior
parietal lobule, left supramarginal
gyrus and the left superior frontal
gyrus). Orange, DAN mask. b
VISAS: green, areas of enhanced
connectivity within the VISAS
network (right lateral occipital
cortex). Magenta, VISAS mask. c
SM: blue, areas within the SM
network (superior and medial
frontal gyrus and precentral
gyrus) of enhanced connectivity.
Pink, SM mask. L, left; R, right
Table 3 Association between
clinical data and behavioural
results for the NNRTI study
Mean values (SD) SSRT (p) RT (p) Accuracy (p)
Years with HIV 14.0 (5.2) 0.99 0.645 0.59
Years on efavirenz 4.8 (3.1) 0.02 0.18 0.20
CD4 count (cells/μL) 601.7 (168.7) 0.38 0.35 0.56
CD8 count (cells/μL) 551.6 (150.8) 0.89 0.35 0.56
CD4/CD8 ratio 1.1 (0.3) 0.51 0.35 0.69
Years with HIV and years on efavirenz are expressed in years, CD4 and CD8 count in (cells/μL). (p), p value,
obtained using a repeated-measure ANOVA
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important role of the DAN in HIV-associated cognitive disorders
(Ernst et al. 2002). The DAN is responsible for covert spatial
attention, saccade planning and visual working memory (Vossel
et al. 2014). Several fMRI studies have shown a greater load-
dependent increase in activation in brain regions related to visual
attention tasks (especially in the prefrontal and posterior parietal
cortex) in PWH compared with healthy controls (Chang et al.
2008; Ernst et al. 2009), suggesting an increased brain metabo-
lism due to an enhanced neuronal activity that could compensate
for the underlying injury to the neural substrate caused by HIV
infection. The driver of this attentional overload in PWH is large-
ly unknown, and our study is one of the first to specifically assess
the issue of the changes exerted by different cART regimens on
the DAN.
In the NNRTI study, in PWH switching to an efavirenz-free
cART, we observed improved attention through changes in the
DAN. Specifically, our data indicate that the right superior pa-
rietal lobule (SPL) is the brain area which shows the highest
vulnerability to efavirenz-induced damage. The role of the SPL
in visuospatial attention has been previously reported by inde-
pendent groups and different techniques (Fink et al. 2000; Fink
et al. 2001; Wu et al. 2016; Vallar et al. 2014) and shows clear
right lateralization, with the right posterior SPL showing stron-
ger anatomical connections with the ipsilateral middle frontal
gyrus (MFG) and inferior frontal gyrus (IFG), and with the
contralateral posterior parietal cortex (PPC) than the left poste-
rior SPL (Wu et al. 2016), accounting for the right predomi-
nance of visuospatial attention control. Interestingly, recent
fMRI and MEG studies showed that the right SPL expresses
the highest attentional load effect both in healthy controls and
PWH under cART (Chang et al. 2008) and correlates with
cognitive impairment in PWH (Becker et al. 2013).
Therefore, the clear right lateralization of our finding is not
surprising, though a bigger sample would be required to con-
firm its specificity. It is possible that efavirenz may cause a
dysfunction of the DAN that is ameliorated, at least partially,
by switching to rilpivirine. Moreover, since the DAN is activat-
ed during top-down feature-based attention, this would well
reflect the improvements in the Groton Maze Learning Test,
Chase Test and One Back Test. Therefore, while our results are
in line with previous data on the role of the DAN dysfunction in
PWH, we were able to dissect the differential impact that spe-
cific drugs can exert on this RSN.
The involvement of the VISAS, which is responsible for
higher-level visual processing such as viewing complex stimuli
and discrimination of locations in space, is not a surprising find-
ing, given the fact that it constitutes one of themain projections to
the DAN. Indeed, in the INSTI study, the finding of an enhanced
connectivity in the left regions of the DAN and the right VISAS
which are functionally highly correlated to the right regions of
the DAN may suggest a compensatory mechanism due to an
underlying damage of visuospatial processing and perceptual
abilities. Sensory-motor function has been traditionally regarded
as significantly impaired in PWH, especially in more severe
cases and in the pre-cART era (Ances and Clifford 2008).
However, it is still largely unknown the impact of different
cART regimens on this network and further studies are needed
in order to validate the relevance of this result.
There are limitations to our work. First, there is no HIV-
negative control arm, and therefore, a comparison between
subjects switching NNRTI and INSTI and healthy controls
would have strengthened our interpretation of the compar-
isons found. However, the INSTI group findings, where no
change was observed, would suggest that the NNRTI find-
ings were the result of the switch form from efavirenz to
rilpivirine rather than a repeated measures effect. Although
De Plessis et al. (Du Plessis et al. 2015) showed comparable
SSRTs between healthy controls and drug-naïve PWH, no
study is currently available on SSRT differences between
healthy controls and people PWH on efavirenz or rilpivirine
containing cART. Secondly, the PROMs are self-reported
questionnaires, so we cannot fully exclude a response shift
bias, as is an intrinsic limitation of all self-reported ques-
tionnaires. Thirdly, these results should be considered ex-
ploratory, given the small sample size may limit our power
of observation. As an example, we have applied fMRI pow-
er (Mumford 2012) to our current results in the NNRTI
study to estimate the sample required to detect a difference
in the insula for the contrast STOP > GO. We estimated that
for 80% power, a group of 30 participants should be suffi-
cient. Moreover, it is known that physiological noise such
as cardiac and respiratory signals can bias fMRI results.
Data required for sophisticated correction procedure such
as physiological noise model (PNM) was not available for
this study, and we based our denoising procedures on ICA-
AROMA and visual assessment of noise components.
Given that our areas of interest are far from the anatomical
structures that are most susceptible to these artefacts (e.g.
brainstem), we are confident that our data reflect a neural
effect. Finally, we used 2 slightly different approaches for
the ICAs of the 2 datasets: while in the INSTI study, we a
priori set the number of components at 20; in the NNRTI,
we let this number to be determined by the algorithm. Both
approaches are valid and used within the neuroimaging
community; in our case, the specific method was chosen
to ensure the best fitting of our data to previously described
RSNs. From a clinical perspective since attention distur-
bances, insomnia and anxiety are among the most common
side effects of both efavirenz and dolutegravir and account
for a high degree of therapy discontinuation (Apostolova
et al. 2015; Hoffmann et al. 2017), we believe that the
improvements in PSQI and HADS could play a major role
in increasing medication adherence, while we argue that the
change in functional connectivity of the DAN, VISAS and
sensory-motor network could explain the reported lack of
concentration and slower psychomotor function.
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Conclusion
In conclusion, evidence that fMRI changes are detectable in vi-
rologically suppressed, neurologically asymptomatic PWH on
cART provides encouraging data on the potential use of these
techniques as possible biomarker of CNS injury related to cART.
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